TauRx was established to address one of the world’s biggest challenges – beating Alzheimer’s disease and other degenerative brain disorders through a completely new approach. A leader in Alzheimer’s research, the company’s mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative disorders.  

TauRx’s strong research team, supported through cooperative relationships with multiple academic institutions around the world, has focussed on the tau pathway, believed to be one of the critical causes of neurodegeneration in the brain. The company’s novel tau aggregation inhibitors (TAIs) target the formation of tau protein ‘tangles’ in the brain, with its lead compound having shown strong pharmacological effect in early trials for participants with mild and moderate Alzheimer's disease. 

The experimental drug has shown to inhibit aggregation of tau, synuclein, TPD-43 and huntingtin proteins. It is currently in development for the treatment and prevention of Alzheimer’s disease, with a pivotal phase 3 clinical trial in progress and results recently disclosed. 

Additionally, TauRx works closely with joint venture company Genting TauRx Diagnostics Ltd (GTD) in the development of ground-breaking new diagnostic tools and blood tests for dementia, which will help transform the treatment pathway for those affected, ensure efficient and early diagnosis and enhance access to treatment and care.   

TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.

Dundee Corporation

Arcane Group

Genting management

TauRx

Is there a link between brain injury and Alzheimer’s disease? 

Research* suggests that up to one third of patients with even a single episode of traumatic brain injury develop abnormal tau tangles, which can lead to the development of dementia. 

To learn more about tau and its role in Alzheimer’s disease, follow our page 📲

#TauFact #TauRx #Dementia #Alzheimers 

*Source: Johnson VE, et al (2012) Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans. Available in Brain Pathol.

Our core values are at the heart of everything we do. 

Swipe below to learn more about our five values: 

🔑 Hard work
🔑 Honesty 
🔑 Teamwork 
🔑 Loyalty 
🔑 Compassion

Read more about our core values here: https://bit.ly/3GRLTYH

#Values #Teamwork #TeamTauRx

📣 TauRx is sponsoring Dementias London 2024! 

As proud partners, we look forward to connecting with fellow professionals to discuss how we can better diagnose, treat and care for those affected by Alzheimer’s disease and other dementias.

Book your place now: https://lnkd.in/eWxWTiZh

#Dementias24 #TauRx

#TauFact: Whilst tau is a healthy protein naturally found in our brains, it may also play a role in the development of dementia. 

This means tau is an important target for the development of a possible treatment. 

Understand more about the formation of damaging tau tangles in Alzheimer’s disease below.

Learn more about the work we do at www.taurx.com
 
#Dementia #Alzheimers

Did you catch the news? 

🏆 TauRx won the Research and Development Achievement Award at the UK Pharma Industry Awards! 

We’re pleased to be recognised for our dedication to researching and developing an effective tau-targeting treatment for Alzheimer’s disease - helping to address one of the great challenges in the medical field. 

Read more in The Telegraph: https://lnkd.in/eNiuPhhM

#PharmaAwards #ResearchandDevelopment #TauRx

How well do you know tau? 

Today’s #TauFact takes us back to basics, explaining the function of tau protein and how it can misfold and lead to dementia. 

Learn more about how this relates to the work we do at https://lnkd.in/eWD3rB3h

#TheTimeForTauIsNow #Dementia #Alzheimers

The risk of dementia among professional footballers has been reported to be almost four times higher than the general population.  
 
A condition called chronic traumatic encephalopathy, or CTE, is prevalent among former players of high-impact sports and shares many features with Alzheimer’s disease. CTE is also a tauopathy but sees tau proteins malfunction due to brain injury, whereas in Alzheimer’s these changes are often due to other factors linked to aging. 
  
Last year, our Head of Medical Affairs, Dr Sonya Miller, spoke to Psychiatric Times to discuss how possible breakthroughs in treatments for Alzheimer’s could hold the key to a treatment for generations of sports people with CTE as well. Read more here: https://bit.ly/3CpS2JK

#TauRx #CTE #Alzheimers #Dementia

It’s the TauRx mission to develop and commercialise products to treat and diagnose the neurodegenerative diseases caused when the tau protein found naturally in our brains misfolds and aggregates.

Hear from our leadership team on how we’re working to achieve this in the video below and learn more about our work: www.taurx.com

Yesterday, Prof. Linda Sommerlade, Dr Sonya Miller, and Jeffrey LaVaute participated in a panel discussion moderated by Jim Pearson, Deputy Chief Executive from Alzheimer Scotland. 

The panel, “Using the patient and caregiver voice to improve our understanding of their experiences living with Alzheimer’s disease” covered important learnings from TauRx and GT Diagnostics’ patient engagement work in Alzheimer’s.

Are you attending the conference? Make sure to drop by our stand and tell us the key insights you’ve learned in the comments 💡

🏆 TauRx won the Research and Development Achievement Award at the UK Pharma Industry Awards! 

Last month, TauRx was recognised for its continuous and dedicated work to develop an effective tau-targeting treatment for Alzheimer’s disease – one of the world’s most urgent unmet medical needs. 

Congratulations to all of the winners 👏

#PharmaAwards #ResearchAndDevelopment #TauRx

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

Google Tag Manager

Apple Mobile Web Clips Icon

Euro

Content Delivery Network

Organization Schema

jsDelivr

PostalAddress Schema

Chief Operating Officer and Chief Business Officer

Glenn Corr

Chief Medical Officer

Richard Stefanacci

Head of Operations (Clinical)

Diane Downie

Head of Operations (Development)

John Cheung

Head of IT and Infrastructure

Julie Reed

Head of People and Culture

Lynn Rankin

Senior Finance Manager UK

Carmen Irving

Associate Records Management and Archiving Lead

Jana Moravcova

Procurement Manager

Scott Rennie

CSV GxP Specialist

Andrew Grolys

Howard Feldman

George Chia

Giovanni Frisoni

Paul Cheng

Sushilan Vasoo

Lon Schneider

Gordon Wilcock

Serge Gauthier

Tim Earle

Chief Business Officer (Aberdeen)

John K S Cheung

Chief Development Officer (Aberdeen)

Jiri Hardlund

Chief Medical Officer (Aberdeen)

Charles Harrington

Chief Scientific Officer (Aberdeen)

Claude Wischik

Co-Founder, Chairman and Chief Executive (Aberdeen)

John Storey

Technical Head (Aberdeen)

Global Logistics and Support Lead (Aberdeen)

Hwang Hong Wei

Finance Director (Singapore)

Asia-Pacific (APAC) Early Stage Companies With Less Than $500M in Revenue

Singapore Companies With More Than 100 Employees

Association of Southeast Asian Nations (ASEAN) Early Stage Companies With More Than 10 Employees

Association of Southeast Asian Nations (ASEAN) Companies (Top 10K)

TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases based on an entirely new approach which targets aggregates of abnormal fibres of Tau protein that form inside nerve cells in the brain. The TauRx team have since discovered that LMTX™ could also have beneficial effects in several other neurodegenerative diseases associated with Tau pathology, as well as other protein aggregation disorders including Parkinson’s, Huntington’s and Frontotemporal Dementia (Pick’s Disease). While TauRx headquarters are in Singapore, its primary research facilities are in Aberdeen, Scotland.

Secondary Market - TauRx Pharmaceuticals

Series A - TauRx Pharmaceuticals

Private Equity Round - TauRx Pharmaceuticals

Venture Round - TauRx Pharmaceuticals

Singapore

Central Region

Asia

TauRx Pharmaceuticals

Dundee Corporation Completes Sale of 8,000 Shares of TauRx Pharmaceuticals Ltd. for Proceeds of US$1 Million

TauRx seeks UK regulatory approval for tau-targeting Alzheimer’s drug

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease

24-month data indicate sustained cognitive benefits for AD patients with HMTM

Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial

TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer's Disease at the AD/PD™ 2024 Conference ...

Alzheimer's Disease Therapeutics Market Value to Reach USD 30.8 Billion by 2033 | Driven by the Advancements in ...

Global Alzheimer's Therapeutic Market Size, Market ...

United Kingdom

Europe

Malaysia

Pakistan

HTML5

Microsoft Outlook

Adobe Fonts

Google Fonts

F5 NGINX

Google Analytics

Office 365

Google Drive

Vimeo

TauRx Pharmaceuticals Ltd is a biotechnology company focused on developing groundbreaking drugs for the management of neurodegenerative diseases, particularly Alzheimer's Disease and Mild Cognitive Impairment.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	1783b107
crunchbase profile	general	Oct 28, 2024 1:53 PM	9b3be452
li profile	general	Feb 5, 2024 10:46 AM	88de9575
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	b415d9b2
peers	general	Feb 5, 2024 10:46 AM	7ee8590d
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:TAURX

TauRx Pharmaceuticals Ltd